The current perspective and opportunities of small nucleic acid‐based therapeutics
Y Chen, Y Li, C Li, D Zhang, Y Liu… - Drug Development …, 2024 - Wiley Online Library
Compared to traditional small molecule and antibody drugs, RNA‐based drugs offer a
simple design, short research and development cycles, high specificity, broad treatment …
simple design, short research and development cycles, high specificity, broad treatment …
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
X Cai, S Peng, S Mu, S Lei, J Li, X Tang… - Expert Opinion on Drug …, 2024 - Taylor & Francis
Background Randomized clinical trials have reported some safety profiles in inclisiran, but
adverse events in real-world remain insufficient. We aim to evaluate the safety of inclisiran in …
adverse events in real-world remain insufficient. We aim to evaluate the safety of inclisiran in …
Comment on “Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials”
HS Rangwala, H Fatima, F Riaz… - Current Problems in …, 2024 - Elsevier
The study" Inclisiran siRNA technology in the management of dyslipidemia: A narrative
review of clinical trials" evaluates inclisiran's efficacy and safety in reducing LDL cholesterol …
review of clinical trials" evaluates inclisiran's efficacy and safety in reducing LDL cholesterol …
[引用][C] Clinical application of small interfering RNA in cardiovascular diseases: A bibliometric analysis
J Lv, K Zou, K Kang - Asian journal of surgery, 2024 - pubmed.ncbi.nlm.nih.gov
Clinical application of small interfering RNA in cardiovascular diseases: A bibliometric analysis
Clinical application of small interfering RNA in cardiovascular diseases: A bibliometric analysis …
Clinical application of small interfering RNA in cardiovascular diseases: A bibliometric analysis …